Absence of differential effect of ticagrelor versus prasugrel maintenance dose on endothelial function in patients with stable coronary artery disease

Area of Science:

• Cardiology
• Pharmacology
• Vascular Biology

Background:

• Endothelial dysfunction is a hallmark of coronary artery disease (CAD).
• Ticagrelor's potential adenosine-mediated mechanisms may improve endothelial function.
• Comparing ticagrelor and prasugrel effects on endothelial function in stable CAD is crucial.

Purpose of the Study:

• To assess the impact of ticagrelor versus prasugrel on endothelial function in stable CAD patients.
• To investigate potential differences in endothelial function mediated by adenosine pathways.

Main Methods:

• Prospective, randomized, crossover study in 22 stable CAD patients.
• Patients received ticagrelor 90 mg twice daily or prasugrel 10 mg once daily for 15 days each, with crossover.
• Endothelial function assessed using peripheral arterial tonometry (EndoPAT) measuring Reactive Hyperemia Index (RHI).

Main Results:

• No significant difference in RHI between ticagrelor and prasugrel treatments (1.78 vs 1.88).
• The rate of endothelial dysfunction (RHI <1.67) was similar for both drugs (45.5% vs 45.5%).
• The difference in RHI between treatments was not statistically significant (p=0.5).

Conclusions:

• Ticagrelor did not demonstrate a significant alteration in endothelial function compared to prasugrel in stable CAD patients.
• Peripheral arterial tonometry did not reveal differences in endothelial function between the two antiplatelet agents.
• Further research may be needed to explore ticagrelor's effects on endothelial function via other mechanisms.